DRUG DISCOVERY TODAY
Scope & Guideline
Advancing the Frontiers of Drug Discovery
Introduction
Aims and Scopes
- Drug Discovery and Development Processes:
The journal covers comprehensive aspects of drug discovery, including target identification, lead discovery, optimization, and preclinical and clinical development. - Innovative Therapeutic Strategies:
It highlights novel therapeutic approaches, including small molecules, biologics, and combination therapies aimed at addressing complex diseases. - Technological Integration:
The journal emphasizes the integration of advanced technologies such as artificial intelligence, machine learning, and nanotechnology in the drug discovery process. - Regulatory Perspectives:
It discusses the regulatory challenges and frameworks that impact drug development, ensuring compliance with evolving standards in the pharmaceutical industry. - Emerging Therapeutic Targets and Modalities:
The journal explores new molecular targets and therapeutic modalities, including gene and cell therapies, immunotherapies, and precision medicine. - Interdisciplinary Collaboration:
It promotes collaboration between academia and industry to foster innovation in drug discovery, emphasizing the importance of cross-disciplinary research.
Trending and Emerging
- Artificial Intelligence in Drug Discovery:
The application of AI and machine learning in drug discovery is rapidly growing, facilitating data analysis, predictive modeling, and innovative approaches to target identification. - Nanotechnology and Nanomedicine:
There is an increasing focus on nanotechnology applications in drug delivery systems, enhancing therapeutic efficacy and reducing side effects. - Immunotherapies and Personalized Medicine:
Research on immunotherapies, especially in oncology, and personalized medicine approaches is trending, reflecting the shift towards tailored therapeutic strategies. - Gene and Cell Therapies:
Emerging interest in gene and cell therapies is notable, with advancements in CRISPR technologies and vector design for targeted therapeutic applications. - Multi-Target Strategies:
The exploration of multi-target drugs and polypharmacology is gaining traction as researchers seek to address complex diseases with multifactorial approaches. - Sustainable Drug Development:
There is a growing emphasis on environmentally sustainable practices in drug development, including greener chemistry and biodegradable materials.
Declining or Waning
- Traditional Drug Repurposing:
While drug repurposing remains a relevant strategy, the focus on traditional methods has waned as novel approaches to drug discovery gain traction. - Conventional Small Molecule Approaches:
There is a noticeable decline in papers exclusively focused on conventional small molecule drug design, with more emphasis now on biologics and combination therapies. - Single-Target Drug Development:
The exploration of single-target drugs is decreasing as the field shifts towards multi-target strategies and polypharmacology to enhance therapeutic efficacy. - Efficacy Studies without Mechanistic Insights:
There is a decline in studies that report efficacy without delving into the underlying mechanisms, as the scientific community increasingly values mechanistic understanding. - Focus on Established Therapeutics:
Research centered on established therapeutics is declining in favor of innovative and experimental approaches that address unmet medical needs.
Similar Journals
Annual Review of Pharmacology and Toxicology
Pioneering knowledge in pharmacology and toxicology.Annual Review of Pharmacology and Toxicology is a leading journal published by ANNUAL REVIEWS, renowned for its comprehensive and critical reviews of the fields of pharmacology and toxicology. With an esteemed history spanning from 1965 to the present and an impressive Q1 ranking in both categories, this journal stands at the forefront of scholarly communication in pharmacological sciences. Researchers are encouraged to submit cutting-edge studies that advance knowledge and innovation in drug development, safety assessments, and therapeutic practices. Although this journal does not currently offer Open Access options, it remains a vital resource for professionals and students who seek to stay updated with the latest high-impact research findings. The journal is indexed in Scopus, boasting remarkable rankings, including Rank #1 in Toxicology and Rank #4 in Pharmacology, reflecting its pivotal role in shaping the discourse in these dynamic fields.
EXPERT OPINION ON THERAPEUTIC TARGETS
Exploring novel strategies for impactful therapeutic solutions.Expert Opinion on Therapeutic Targets, published by Taylor & Francis Ltd, is a highly respected journal in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. With a focus on cutting-edge research and innovative approaches to therapeutic development, this journal has established itself as a leading platform for scholars and practitioners, boasting a prestigious Q1 ranking across multiple categories in 2023. The journal aims to present expert perspectives on novel therapeutic strategies, promising drug candidates, and insights into the intricate mechanisms underlying various diseases. Its impressive impact factor reflects the journal's commitment to advancing scientific knowledge and influencing clinical practice. With its inception in 1997 and ongoing publication through to 2024, Expert Opinion on Therapeutic Targets continues to be an invaluable resource for those seeking to stay at the forefront of therapeutic innovations.
Nucleic Acid Therapeutics
Fostering Collaboration in Nucleic Acid Therapeutics.Nucleic Acid Therapeutics is a leading peer-reviewed journal published by Mary Ann Liebert, Inc that focuses on the forefront of research in the fields of biochemistry, drug discovery, genetics, and molecular medicine. With an impressive Q1 ranking across multiple categories, including biochemistry and drug discovery, the journal aims to disseminate innovative findings on nucleic acid-based therapies, their mechanisms, and clinical applications. The journal is dedicated to advancing the understanding of nucleic acids in the development of new therapeutic strategies, appealing to a diverse audience of researchers, professionals, and students alike. Given its commitment to open access publishing, Nucleic Acid Therapeutics ensures that groundbreaking research is accessible, fostering collaboration and dialogue in this critical area of scientific inquiry. Situated in the United States, Nucleic Acid Therapeutics plays a pivotal role in connecting researchers and practitioners in the ever-evolving landscape of molecular medicine and biotechnology.
Current Reviews in Clinical and Experimental Pharmacology
Unlocking the Future of Therapeutics Through Open AccessCurrent Reviews in Clinical and Experimental Pharmacology is a cutting-edge journal published by Bentham Science Publishers in the United Arab Emirates, focusing on the dynamic field of pharmacology. With an ISSN of 2772-4328 and an E-ISSN of 2772-4336, this journal has rapidly established itself as a significant resource for researchers and professionals in the medical and pharmaceutical sciences since its inception in 2021. It boasts an impressive Q3 ranking in Pharmacology (medical) and Q2 in the Pharmacology, Toxicology and Pharmaceutics (miscellaneous) category as of 2023. Furthermore, it ranks #14/80 in general pharmacology, reflecting its esteemed position within the scientific community. As an Open Access publication, it ensures that groundbreaking research is readily accessible, fostering collaboration and innovation. The journal invites high-quality reviews and original articles that address contemporary issues and advancements in clinical and experimental pharmacology, making it an essential venue for disseminating knowledge and engaging with emerging trends in therapeutic developments.
MOLECULAR CANCER THERAPEUTICS
Advancing cancer therapy through molecular insights.MOLECULAR CANCER THERAPEUTICS, published by the American Association for Cancer Research, is a premier journal dedicated to advancing the field of cancer research and therapy since 2001. With a notable impact factor reflecting its high-quality content, this journal stands out in the Q1 category for both Cancer Research and Oncology as of 2023. Researchers, clinicians, and students interested in innovative treatment strategies and molecular mechanisms can find valuable insights within its pages, bolstered by a rigorous peer-review process and a global perspective on cancer therapeutic developments. Although the journal operates under a subscription model, it provides comprehensive access to cutting-edge studies and reviews that drive forward the understanding of cancer biology and treatment modalities. The journal's impressive Scopus rankings further validate its influence within both oncology and the broader cancer research community, making it an indispensable resource for anyone committed to combating cancer through science.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Elevating Research in Alimentary PharmacologyALIMENTARY PHARMACOLOGY & THERAPEUTICS, published by Wiley, is a premier scholarly journal in the fields of gastroenterology, hepatology, and pharmacology. With an impressive impact factor and ranking in the top quartile (Q1) of its classifications, the journal is recognized for its rigorous peer-reviewed research and comprehensive reviews, aiming to advance the understanding of therapeutic interventions in gastrointestinal and liver diseases. Since its inception in 1987, it has become an essential resource for researchers, healthcare professionals, and students alike, fostering scientific dialogue and innovation. With a Scopus rank placing it in the 97th percentile for pharmacology and 96th for gastroenterology, it is dedicated to publishing the most significant and impactful findings in the field. ALIMENTARY PHARMACOLOGY & THERAPEUTICS thus plays a vital role in shaping the future of medical treatments and interventions in gastrointestinal health.
Medicinal Chemistry
Driving excellence in medicinal chemistry and toxicology.Medicinal Chemistry is a prestigious journal published by Bentham Science Publishers Ltd, dedicated to advancing the field of drug discovery and development. Established in 2005 with a converged publication timeframe extending to 2024, this journal serves as a vital resource for researchers and professionals interested in the intricate processes of medicinal chemistry, pharmacology, and toxicology. With an ISSN of 1573-4064 and an E-ISSN of 1875-6638, it has established a notable presence in the academic community, currently positioned in Q3 of Drug Discovery category according to the 2023 quartiles. The journal's ranking in Scopus places it at 90 out of 157 in its field, showcasing its impact and relevance, with a percentile standing of 42. Although the journal is not open access, it continues to provide insightful articles and research findings that contribute significantly to the understanding and innovation in medicinal chemistry. Based in the United Arab Emirates, Medicinal Chemistry is committed to disseminating high-quality research that shapes the future of drug formulation and therapeutic advancement.
EXPERT OPINION ON THERAPEUTIC PATENTS
Illuminating the Path of Drug Development Through Expert CommentaryEXPERT OPINION ON THERAPEUTIC PATENTS, published by Taylor & Francis Ltd, is a prestigious journal dedicated to the critical analysis and commentary on therapeutic patents, emphasizing their impact on drug discovery and development. With an improving reputation reflected in its 2023 Q1 rankings in Drug Discovery and Pharmacology, this journal stands out as a leading source in the fields of pharmacology and medicine, holding significant relevance with a Scopus ranking in the 90th percentile for its contributions in Drug Discovery and a robust position in Pharmacology. Launched in 1991, the journal consistently engages researchers and professionals seeking to stay at the forefront of innovations in therapeutic patents, thus driving advancements in the pharmaceutical landscape. Although it does not offer Open Access, its comprehensive scope and commitment to quality make it an essential resource for those looking to explore the intersection of intellectual property and pharmacological research.
CANCER RESEARCH
Elevating the standards of cancer research and innovation.Cancer Research, published by the American Association for Cancer Research, is a premier journal in the field of oncology, renowned for its commitment to advancing cancer research since its inception in 1941. With an impressive impact factor reflecting its vital role in the field, this journal consistently ranks in the Q1 quartile for both Cancer Research and Oncology, positioning it among the top 7.5% of journals in these categories. The journal serves as a crucial platform for researchers, professionals, and students to disseminate and gain insights into groundbreaking studies that shape our understanding of cancer biology, prevention, diagnosis, and treatment. While it is not an open-access publication, its rigorous peer-review process ensures that only high-quality research is published, thus maintaining a standard of excellence in the scientific community. With a strong legacy and an ever-expanding influence, Cancer Research continues to be essential for anyone dedicated to the fight against cancer, showcasing cutting-edge research that drives scientific discovery and innovation.
Biologics-Targets & Therapy
Connecting Laboratory Insights with Clinical PracticeBiologics-Targets & Therapy is a leading open access journal published by DOVE MEDICAL PRESS LTD, specializing in the fields of Gastroenterology, Immunology and Allergy, Oncology, Pharmacology (Medical), and Rheumatology. Launched in 2007, the journal has established a solid reputation for disseminating high-quality research that bridges the gap between laboratory findings and clinical application, offering insights into the therapeutic potential of biologics. With a commendable impact factor and placement in Q1 quartiles across multiple medical domains in 2023, Biologics-Targets & Therapy ranks among the top journals in its categories, providing a platform for researchers and clinicians to share their latest discoveries. Researchers can access articles freely, promoting wider dissemination and collaboration in the scientific community. By publishing innovative studies and reviews, this journal plays a pivotal role in advancing the understanding and therapeutic applications of biologics, making it an essential resource for professionals and students alike.